Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04082442 · ClinicalTrials.gov registry record · Phase 2
Evolocumab in Patients With Acute MI
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT04082442: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT04082442 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04082442, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Vascular and myocardial inflammation are significantly increased in Acute Coronary Syndrome (ACS) patients, are closely correlated to LDL-C levels, and are associated with these adverse consequences in the post-ACS patient population. Serum proprotein convertase subtilisin/kerin type 9 (PCSK9) levels are also increased in ACS, may raise LDL-C, and the investigators' pre-clinical studies indicate that PCSK9 is also a potent inducer of vascular inflammation. The addition of the PCSK9 antibody evolocumab, currently approved to lower LDL-C in certain patient populations, to current medical therapies would appear to be of particular benefit in patients with an ACS by markedly reducing LDL-C, stabilizing vulnerable plaque, and limiting inflammation-associated myocardial cell loss and resultant dysfunction.
Interventions
- DRUG Placebos
- DRUG Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2024-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04082442
The ClinicalTrials.gov registry entry for NCT04082442 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT04082442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04082442 about?
NCT04082442 is a clinical study titled "Evolocumab in Patients With Acute MI". Vascular and myocardial inflammation are significantly increased in Acute Coronary Syndrome (ACS) patients, are closely correlated to LDL-C levels, and are associated with these adverse consequences in the post-ACS patient population. Serum proprotein convertase subtilisin/kerin type 9 (PCSK9) level...
What is the current status of trial NCT04082442?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2019-09-01. Estimated completion is 2024-10-25.
What interventions are being tested in trial NCT04082442?
The interventions under investigation include: Placebos (DRUG), Evolocumab (DRUG).
Who is sponsoring clinical trial NCT04082442?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.